Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today
Sanofi’s pipeline remodeling program has claimed a pivotal combo approach to lung cancer along with a score of other terminations in Q4. And the moves underscore what’s hot — and not — in the oncology field.
Outlining the moves in their quarterly sit-down with analysts, Sanofi hit the kill switch on 13 development programs and 25 research projects. But the R&D group also hit the gas on 17 programs, about half of which are in oncology.
New R&D chief John Reed is pressing a strategy established by Elias Zerhouni, which involves more of an in-house focus, particularly in the wake of the recent Ablynx and Bioverativ buyouts, which added new research capabilities and drugs to the pipeline.
Basic subscription required
Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.